ARTICLE | Clinical News
Alagebrium: Phase II delayed
February 28, 2005 8:00 AM UTC
ALT halted enrollment in a double-blind, placebo-controlled, U.S. Phase II trial due to preclinical toxicity in rats (see BioCentury, Jan. 3). The trial will continue in the patients already enrolled....